JTC-801 free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596304

CAS#: 244218-93-7

Description: JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist, binding to ORL1 receptor with a Ki value of 8.2 nM.


Chemical Structure

img
JTC-801 free base
CAS# 244218-93-7

Theoretical Analysis

MedKoo Cat#: 596304
Name: JTC-801 free base
CAS#: 244218-93-7
Chemical Formula: C26H25N3O2
Exact Mass: 411.1947
Molecular Weight: 411.5
Elemental Analysis: C, 75.89; H, 6.12; N, 10.21; O, 7.78

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: JTC-801 free base; JTC-801;

IUPAC/Chemical Name: N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide

InChi Key: VTGBZWHPJFMTKS-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H25N3O2/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30)

SMILES Code: O=C(NC1=CC=C2N=C(C)C=C(N)C2=C1)C3=CC=CC=C3COC4=CC=C(CC)C=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 411.5 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Li JX, Bi YP, Wang J, Yang X, Tian YF, Sun ZF. JTC-801 inhibits the proliferation and metastasis of ovarian cancer cell SKOV3 through inhibition of the PI3K - AKT signaling pathway. Pharmazie. 2018 May 1;73(5):283-287. doi: 10.1691/ph.2018.7326. PubMed PMID: 29724295.

2: Zheng CJ, Yang LL, Liu J, Zhong L. JTC-801 exerts anti-proliferative effects in human osteosarcoma cells by inducing apoptosis. J Recept Signal Transduct Res. 2018 Apr;38(2):133-140. doi: 10.1080/10799893.2018.1436561. Epub 2018 Feb 15. PubMed PMID: 29447541.

3: Song X, Zhu S, Xie Y, Liu J, Sun L, Zeng D, Wang P, Ma X, Kroemer G, Bartlett DL, Billiar TR, Lotze MT, Zeh HJ, Kang R, Tang D. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology. 2018 Apr;154(5):1480-1493. doi: 10.1053/j.gastro.2017.12.004. Epub 2017 Dec 14. PubMed PMID: 29248440; PubMed Central PMCID: PMC5880694.

4: Gorbunov AS, Vaizova OE, Belousov MV, Pozdnyakova SV, Nesterov EA, Madonov PG. Role of Endogenous Agonists of Opioid Receptors in the Regulation of Heart Resistance to Postischemic Reperfusion Injury. Bull Exp Biol Med. 2017 Nov;164(1):18-20. doi: 10.1007/s10517-017-3916-6. Epub 2017 Nov 9. PubMed PMID: 29119401.

5: da Silva JA, Biagioni AF, Almada RC, de Freitas RL, Coimbra NC. Panicolytic-like effects caused by substantia nigra pars reticulata pretreatment with low doses of endomorphin-1 and high doses of CTOP or the NOP receptors antagonist JTC-801 in male Rattus norvegicus. Psychopharmacology (Berl). 2017 Oct;234(20):3009-3025. doi: 10.1007/s00213-017-4678-6. Epub 2017 Aug 30. PubMed PMID: 28856406.

6: Hiramoto K, Yokoyama S, Yamate Y. Ultraviolet A eye irradiation ameliorates colon carcinoma induced by azoxymethane and dextran sodium sulfate through β-endorphin and methionine-enkephalin. Photodermatol Photoimmunol Photomed. 2017 Mar;33(2):84-91. doi: 10.1111/phpp.12290. Epub 2017 Jan 19. PubMed PMID: 28039905.

7: Ulugol A, Topuz RD, Gunduz O, Kizilay G, Karadag HC. Changes in nociceptin/orphanin FQ levels in rat brain regions after acute and chronic cannabinoid treatment in conjunction with the development of antinociceptive tolerance. Fundam Clin Pharmacol. 2016 Dec;30(6):537-548. doi: 10.1111/fcp.12215. Epub 2016 Jul 14. PubMed PMID: 27371029.

8: Hiramoto K, Sugiyama D, Takahashi Y, Mafune E. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness. Biomed Pharmacother. 2016 May;80:16-22. doi: 10.1016/j.biopha.2016.02.013. Epub 2016 Mar 14. PubMed PMID: 27133035.

9: Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, Lucki I. Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors. Neuropsychopharmacology. 2016 Aug;41(9):2344-51. doi: 10.1038/npp.2016.38. Epub 2016 Mar 16. PubMed PMID: 26979295; PubMed Central PMCID: PMC4946065.

10: Otsuka A, Kabashima K. [BARRIER FUNCTION AND CUTANEOUS IMMUNOLOGY]. Arerugi. 2015 Sep;64(9):1189-95. doi: 10.15036/arerugi.64.1189. Review. Japanese. PubMed PMID: 26657906.

11: Yawata T, Higashi Y, Shimizu T, Shimizu S, Nakamura K, Taniuchi K, Ueba T, Saito M. Brain opioid and nociceptin receptors are involved in regulation of bombesin-induced activation of central sympatho-adrenomedullary outflow in the rat. Mol Cell Biochem. 2016 Jan;411(1-2):201-11. doi: 10.1007/s11010-015-2582-0. Epub 2015 Oct 1. PubMed PMID: 26427671.

12: Ertin IH, Gunduz O, Ulugol A. Contribution of nociceptin/orphanin FQ receptors to the anti-nociceptive and hypothermic effects of dipyrone. Acta Neuropsychiatr. 2015 Feb;27(1):48-52. doi: 10.1017/neu.2014.38. Epub 2014 Dec 3. PubMed PMID: 25467825.

13: Zhang Y, Simpson-Durand CD, Standifer KM. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder. Br J Pharmacol. 2015 Jan;172(2):571-82. doi: 10.1111/bph.12701. Epub 2014 Jul 1. PubMed PMID: 24666365; PubMed Central PMCID: PMC4292969.

14: Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther. 2014 Mar;141(3):283-99. doi: 10.1016/j.pharmthera.2013.10.011. Epub 2013 Nov 1. Review. Erratum in: Pharmacol Ther. 2014 Sep;143(3):351. PubMed PMID: 24189487; PubMed Central PMCID: PMC5098338.

15: Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, Nakashima C, Nakajima S, Watanabe T, Miyachi Y, Narumiya S, Kabashima K. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol. 2014 Jan;133(1):139-46.e1-10. doi: 10.1016/j.jaci.2013.07.027. Epub 2013 Sep 20. PubMed PMID: 24055295.

16: Delaney G, Dawe KL, Hogan R, Hunjan T, Roper J, Hazell G, Lolait SJ, Fulford AJ. Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats. J Neuroendocrinol. 2012 Dec;24(12):1527-41. doi: 10.1111/j.1365-2826.2012.02361.x. PubMed PMID: 22835008; PubMed Central PMCID: PMC3546383.

17: Gunduz O, Karadag HC, Ulugol A. Synergistic anti-allodynic effects of nociceptin/orphanin FQ and cannabinoid systems in neuropathic mice. Pharmacol Biochem Behav. 2011 Oct;99(4):540-4. doi: 10.1016/j.pbb.2011.05.029. Epub 2011 Jun 6. PubMed PMID: 21664922.

18: Del Giudice MR, Borioni A, Bastanzio G, Sbraccia M, Mustazza C, Sestili I. Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor. Eur J Med Chem. 2011 Apr;46(4):1207-21. doi: 10.1016/j.ejmech.2011.01.040. Epub 2011 Feb 3. PubMed PMID: 21330016.

19: Borioni A, Bastanzio G, Delfini M, Mustazza C, Sciubba F, Tatti M, Del Giudice MR. High resolution NMR conformational studies of new bivalent NOP receptor antagonists in model membrane systems. Bioorg Chem. 2011 Feb;39(1):59-66. doi: 10.1016/j.bioorg.2010.12.001. Epub 2010 Dec 17. PubMed PMID: 21211814.

20: Mahmoud S, Margas W, Trapella C, Caló G, Ruiz-Velasco V. Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons. Mol Pharmacol. 2010 May;77(5):804-17. doi: 10.1124/mol.109.062208. Epub 2010 Feb 16. PubMed PMID: 20159949; PubMed Central PMCID: PMC2872970.